ABT Stock Recent News

Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list.

Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.

Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries ABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries prior to stenting.

The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net income margin of 31.95% and generates over $8.5 billion in cash from operations, providing significant flexibility. Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets.